Medicine Episodes

8
Aug. 21, 2026

Milestone Prescription Price Drops and the CTE Diagnostic Puzzle

Friday, August 21, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Eva Johnson cover a historic drop in prescription drug prices. Prices fell 3.1% over the past year, the steepest annual decline since 1963, and the anchors unpack what is actually driving it from generics to GLP-1 competition to the Inflation Reduction Act. They also break down why the national index does not always match what patients pay at the pharmacy counter. Plus: a split between two studies on whether CTE c...
7
Aug. 14, 2026

FDA Approves mRNA Flu Shot and AI Learns to Build Viruses

Friday, August 14, 2026 In today's episode, Adam Rose (@adjoro) & Dr. Alok Patel (@alokpatelmd) cover the FDA's landmark approval of Moderna's first mRNA flu vaccine for adults. They break down the phase-three trial showing the mRNA shot produced fewer confirmed influenza cases than standard vaccines, and what a complicated insurance landscape means for access this flu season. Plus: researchers at the Arc Institute fed millions of viral DNA sequences to a language model. It wrote new genomes th...
6
Aug. 7, 2026

Blood Donation Crisis & A 4-Organ Transplant First

August 7, 2026 In today's episode, Dr. Will Flanary (@DrGlaucomflecken) & Eva Johnson cover the American Red Cross declaring its second-ever national blood crisis, with Type O blood critically low and hospitals postponing transfusions. They break down what's driving the shortage and debate whether blood donors deserve HOV-lane perks. Then: a 36-year-old Iowa woman with cystic fibrosis becomes the first known U.S. patient to receive a quadruple organ transplant involving re-transplanted lungs, in...
July 31, 2026

The ChatGPT Medical Lawsuit & Why Statin Rules Just Changed

Friday, July 31, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a Florida man's lawsuit against OpenAI after ChatGPT repeatedly dismissed his pulmonary embolism symptoms as "not something dangerous." The case raises urgent questions about AI medical liability just as a new JAMA analysis reveals updated cholesterol guidelines now make 87.5 million US adults eligible for statins (more than 56% of the 30-to-79 population). Plus: they also discuss the FDA's first ...
July 24, 2026

Kalshi Prediction Market and CMS's 2027 Fee Schedule Overhaul

Friday, July 24, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover CMS's sweeping 2027 physician fee schedule proposal, which would accelerate Medicare's shift from fee-for-service toward value-based, preventive care. They also unpack Kalshi's launch of clinical trial prediction markets; betting on FDA approvals is now a real thing, and the ethical questions are piling up. Coffee gets a heart health endorsement from the AHA, and an outbreak of Legionnaires' disease hits ...
3
July 17, 2026

Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell

Friday, July 17, 2026 In today’s episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) and Adam Rose cover the EPCAT III trial, which found that aspirin alone was non-inferior to an initial course of rivaroxaban followed by aspirin for preventing major blood clots after elective hip or knee replacement in predominantly standard-risk patients. They examine NICE’s draft recommendation allowing two rapid endometriosis tests, EndoSure and Endotest, to enter limited NHS use while resear...
2
July 10, 2026

Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread

Friday, July 10, 2026 In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the end of 2027, and why that copay sits outside normal Part D accounting. They also track a Cyclospora outbreak now reported across 18 states and why routine washing does not reliably kill it. Plus: they also discuss Alibaba's $600 million fentanyl-precursor settlement, the WHO's first emergency-use Ebola (Bundibugyo) diagnostic, France's deadly heat wave, and more.